GlaxoSmithKline And Theravance Announce Start Of Large Phase 2B ICS And LABA Studies For Asthma In The Horizon Programme

GlaxoSmithKline Plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced the start of large Phase 2b asthma dose-optimisation studies with both the lead inhaled corticosteroid (ICS) GW685698 (’698) and the lead long-acting beta agonist (LABA) GW642444 (’444) assets in the ‘Horizon’ programme to develop a next-generation combination product.

More: continued here

Filed under: Clinical Trials on January 6th, 2008